Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-7246. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 16/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 12/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-7246 SCHEMBL29486331 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| Mk-7246 SCHEMBL2186905 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| Mk-7246 SCHEMBL15428834 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12347583 | 0.90 | PTGDR2 (0.82) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12347569 | 0.90 | PTGDR2 (0.82) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL13137620 | 0.88 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL232733 | 0.88 | PTGDR2 (0.79) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12355439 | 0.88 | PTGDR2 (0.79) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12347578 | 0.87 | PTGDR2 (0.77) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL1770880 | 0.87 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | claimed |
| EP-2342201-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Canada Inc. (CA) | 2011-07-13 | — | — | EP | claimed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | claimed |
| WO-2010031182-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2010-03-25 | — | — | WO | claimed |
| EP-2346865-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2015-07-15 | — | — | EP | disclosed |
| US-20150072963-A1 | COMPOSITIONS AND METHODS FOR REGULATING HAIR GROWTH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2015-03-12 | — | — | US | disclosed |
| US-20150072963-A1 | COMPOSITIONS AND METHODS FOR REGULATING HAIR GROWTH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2015-03-12 | — | — | US | disclosed |
| US-8637541-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| EP-1915372-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2013-11-20 | — | — | EP | disclosed |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| WO-2007019675-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072963-A1 | COMPOSITIONS AND METHODS FOR REGULATING HAIR GROWTH | PTGDR2, PTGDR, PTGER2 | PTGDR2 1/4885PTGDR 2/4885TBXA2R 223/4885 |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MC2R, HRH2, PTGDR | PTGDR2 9/4885PTGDR 3/4885TBXA2R 7/4885 |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, MTNR1B, MTNR1A | PTGDR2 7/4885PTGDR 6/4885TBXA2R 89/4885 |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885PTGDR 1/4885TBXA2R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.